So far, various pharmacological strategies have been used for manipulating cancer-related TGFβ signaling, including, but not limited to, small molecule inhibitors that suppress the receptor kinase activity, antibodies that block ligand-receptor binding, and antisense oligonucleotides that target TGFβ signaling elements [51]. The gene discussed is TGFB1; the disease is cancer.